Physician profile
Michelle L Rampersad
NPI 1518154236
$34,018.45
in general payments reported to CMS, 2019-2025
75 companies · $3,006 in 2025
The $3,006 reported for 2025 was more than what 84% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,761 · 2022: $10K · 2023: $10K · 2024: $3,675 · 2025: $3,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,379 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,960 · Consulting Fee: $2,730 · Travel and Lodging: $1,266 · Education: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,379.02 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,960.00 |
| Consulting Fee | $2,730.00 |
| Travel and Lodging | $1,265.86 |
| Education | $757.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $23,179.67 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Janssen Biotech, INC. | $1,326.05 | 2021-2025 | Rybrevant, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $1,026.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $746.03 | 2021-2025 | Imfinzi, Enhertu, Tagrisso |
| Astellas Pharma US INC | $566.79 | 2021-2025 | Xtandi, Padcev |
| Lilly USA, LLC | $551.65 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $505.91 | 2021-2025 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $482.57 | 2021-2025 | |
| Pfizer INC. | $440.68 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $433.51 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $369.63 | 2021-2025 | |
| Celgene Corporation | $341.25 | 2021-2025 | Reblozyl, Opdualag, Breyanzi |
| Sobi, INC | $309.18 | 2023-2025 | |
| Eisai INC. | $281.02 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $250.02 | 2022-2025 | Iclusig, Fruzaqla, Alunbrig |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $198.77 | 2021-2025 | Tecentriq, Alecensa, Polivy |
| Seagen INC. | $184.68 | 2021-2023 | Tukysa |
| Glaxosmithkline, LLC. | $167.87 | 2023-2025 | Ojjaara, Shingrix, Blenrep |
| E.R. Squibb & Sons, L.L.C. | $152.15 | 2021-2025 | Opdivo, Opdualag |
| Pharmacosmos Therapeutics INC. | $138.73 | 2021-2025 | Monoferric, Cosela |
| Tersera Therapeutics LLC | $127.04 | 2023-2025 | Zoladex |
| Array Biopharma INC | $123.05 | 2021-2025 | Lorbrena, Braftovi, Mektovi |
| Jazz Pharmaceuticals INC. | $105.56 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $104.90 | 2023-2025 | Libtayo |
| Gilead Sciences, INC. | $103.87 | 2023-2025 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $103.25 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $92.76 | 2023-2025 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $84.13 | 2022-2024 | Qinlock |
| Amgen INC. | $74.63 | 2021-2023 | Blincyto, Kyprolis |
| Stemline Therapeutics INC. | $68.08 | 2023-2025 | Orserdu |
| Karyopharm Therapeutics INC. | $66.46 | 2021-2025 | Xpovio |
| Ipsen Biopharmaceuticals, INC | $65.68 | 2021-2025 | Onivyde |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.06 | 2021-2024 | Gilotrif |
| G1 Therapeutics, INC. | $53.51 | 2023 | Cosela |
| Sumitomo Pharma America, INC. | $52.97 | 2023-2025 | Orgovyx |
| Agios Pharmaceuticals, INC. | $52.13 | 2023-2025 | Pyrukynd |
| Morphosys, US INC. | $50.19 | 2021-2023 | Monjuvi |
| Abbvie INC. | $48.82 | 2025 | |
| Geron Corporation | $48.00 | 2025 | Rytelo |
| Pharmacyclics LLC, An Abbvie Company | $46.16 | 2023 | Imbruvica, Epkinly |
| Pharmaessentia USA Corporation | $44.78 | 2023-2024 | Besremi |
| Foundation Medicine, INC. | $41.36 | 2022-2023 | |
| Global Blood Therapeutics, INC. | $38.90 | 2021 | |
| Emd Serono, INC. | $38.32 | 2023-2025 | Bavencio |
| Mirati Therapeutics, INC. | $38.32 | 2023-2024 | Krazati |
| Genmab U.S., INC. | $37.02 | 2024 | Epkinly |
| Rigel Pharmaceuticals, INC. | $36.71 | 2022-2024 | Tavalisse, Rezlidhia |
| Puma Biotechnology, INC. | $36.66 | 2022-2024 | |
| Kyowa Kirin, INC. | $31.89 | 2022 | |
| Kite Pharma, INC. | $30.53 | 2021 | |
| Angiodynamics, INC. | $26.99 | 2023 | Solero |
| Myriad Genetic Laboratories, INC. | $22.78 | 2024 | Myrisk |
| Emmaus Medical, INC. | $21.97 | 2021 | |
| Apellis Pharmaceuticals, INC. | $20.97 | 2023 | Empaveli |
| Azurity Pharmaceuticals, INC. | $20.91 | 2025 | Danziten |
| Tolmar, INC. | $20.68 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $20.68 | 2025 | Rubraca |
| Alnylam Pharmaceuticals INC. | $19.67 | 2025 | Givlaari |
| Springworks Therapeutics, INC. | $19.32 | 2025 | Ogsiveo |
| Novocure INC. | $19.30 | 2025 | Optune Lua (Novottf-200t) |
| Verity Pharmaceuticals INC. | $18.70 | 2024 | Trelstar |
| Cti Biopharma Corp. | $18.52 | 2022 | |
| Dendreon Pharmaceuticals LLC | $18.42 | 2025 | Provenge |
| Immunocore Limited | $17.82 | 2024 | Kimmtrak |
| Beigene USA, INC. | $17.76 | 2024 | Tevimbra |
| Dova Pharmaceuticals | $17.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.94 | 2021 | |
| Acceleron Pharma, INC. | $16.36 | 2021 | |
| Csl Behring | $16.36 | 2024 | Idelvion, Afstyla |
| Myovant Sciences INC. | $15.74 | 2021 | |
| Taiho Oncology, INC. | $15.41 | 2025 | |
| Recordati_rare_diseases_inc. | $14.90 | 2025 | Enjaymo |
| Adaptive Biotechnologies Corporation | $14.65 | 2025 | Clonoseq |
| Iovance Biotherapeutics, INC. | $13.30 | 2025 | Amtagvi |
| Acrotech Biopharma INC. | $10.15 | 2024 | Beleodaq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Rampersad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.